Attached files
| file | filename |
|---|---|
| EX-10.10 - EX-10.10 - KalVista Pharmaceuticals, Inc. | kalv-ex1010_229.htm |
| EX-32.2 - EX-32.2 - KalVista Pharmaceuticals, Inc. | kalv-ex322_236.htm |
| EX-32.1 - EX-32.1 - KalVista Pharmaceuticals, Inc. | kalv-ex321_235.htm |
| EX-31.2 - EX-31.2 - KalVista Pharmaceuticals, Inc. | kalv-ex312_234.htm |
| EX-31.1 - EX-31.1 - KalVista Pharmaceuticals, Inc. | kalv-ex311_233.htm |
| EX-23.2 - EX-23.2 - KalVista Pharmaceuticals, Inc. | kalv-ex232_265.htm |
| EX-21.1 - EX-21.1 - KalVista Pharmaceuticals, Inc. | kalv-ex211_232.htm |
| EX-10.12 - EX-10.12 - KalVista Pharmaceuticals, Inc. | kalv-ex1012_227.htm |
| EX-10.11 - EX-10.11 - KalVista Pharmaceuticals, Inc. | kalv-ex1011_231.htm |
| EX-10.8 - EX-10.8 - KalVista Pharmaceuticals, Inc. | kalv-ex108_228.htm |
| 10-K - 10-K - KalVista Pharmaceuticals, Inc. | kalv-10k_20170430.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-215185 and 333-217009 each on Form S-3 and Registration Statement Nos. 333-203721, 333-215184, 333-216032 and 333-217008 each on Form S-8 of our report dated July 27, 2017, relating to the consolidated financial statements of KalVista Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of KalVista Pharmaceuticals, Inc. for the year ended April 30, 2017.
|
/s/ Deloitte & Touche LLP |
|
|
|
Boston, Massachusetts |
|
July 27, 2017 |